Marlee Matlin Discusses Her Father's Diagnosis of Multiple Myeloma

Six-year PERSEUS results show 81% of newly diagnosed, transplant-eligible myeloma patients had no cancer progression, with many stopping Darzalex.

A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.

Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.

Learn how to cope with life after cancer treatment with Dr. Eric Bengtsen, a psycho-oncology psychiatrist at Memorial Sloan Kettering Cancer Center.

Six years after being diagnosed with B-cell ALL at 21, William Yank opens up about the physical changes of treatment, the emotional weight of constant care and the role hope plays in his survivorship.

A combination of Zenbexus, Darzalex and dexamethasone nearly doubled the rate of deep, MRD-negative responses in relapsed multiple myeloma.

For Blood Cancer Awareness Month, Dr. Guenther Koehne shares why immunotherapy is making this a promising time for people with blood cancers.